Quantcast

Latest drug discovery Stories

2014-05-28 08:33:06

Array to advance kinase inhibitors for inflammatory disease BOULDER, Colo., May 28, 2014 /PRNewswire/ -- Array BioPharma (Nasdaq: ARRY) announced today a collaboration agreement with Biogen Idec (NASDAQ: BIIB) for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO The collaboration target and lead inhibitors were discovered through Array's proprietary...

2014-05-27 23:12:09

Chexx Inc., a company that specializes in issuing and sending stipend payments to clinical trial patients around the world, announced today that they will be exhibiting at the DIA 50th Annual Meeting, June 15-19, 2014 in San Diego. Vancouver, BC (PRWEB) May 27, 2014 Chexx Inc., a company that specializes in issuing and sending stipend payments to clinical trial patients around the world, announced today that they will be exhibiting at the DIA 50th Annual Meeting, June 15-19, 2014 in San...

2014-05-27 23:04:12

Outsourcing in the drug discovery market reached $13 billion in 2013, which increased about 15% from $11 billion in 2012. The global drug discovery outsourcing market is expected to continue a similar growth pattern in the next five years, according to the Kalorama report, “Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 6th Edition.” New York, NY (PRWEB) May 27, 2014 The market for outsourced drug discovery services is robust with an optimistic...

2014-05-27 08:29:32

To lead integration of Company's global scientific expertise and services to meet end-to-end customer drug development needs BOSTON, May 27, 2014 /PRNewswire/ -- PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today named Dr. Sy Pretorius its Chief Scientific Officer. Dr. Pretorius currently serves as the Company's Corporate Vice President and Worldwide Head of Early Phase, and will continue in that capacity in addition to assuming his...

2014-05-21 12:06:57

VTT A team of research scientists from VTT Technical Research Centre of Finland, the University of Turku and the University of Eastern Finland has discovered a previously unknown Cent-1 molecule that kills cancer cells. Their research also shows that new cancer drug candidates can be identified faster and at lower cost by using computer-assisted and cell-based screening of compounds. The objective of the research project led by Marko Kallio, Principal Scientist at VTT, was to accelerate...

2014-05-20 23:09:37

Premier Research presents an exciting live webinar on Tuesday, June 10, 2014 at 11:00am EDT (16:00 UK BST/ GMT +1) examining the trial subject’s knowledge during Neuropsychiatric clinical trials. Toronto, Canada (PRWEB) May 20, 2014 From the imperative to detect cognitive and functional changes as early as possible in the course of Alzheimer’s disease, through the importance of measuring cognitive and attentional effects of investigational drugs in clinical trials, to the...

2014-05-20 12:20:42

Scripps Research Institute Chemists at The Scripps Research Institute (TSRI) have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials in cancer patients. The new report, published this week by the international chemistry journal Angewandte Chemie, focuses on a compound called TIC10. In the new study, the TSRI scientists show that TIC10's structure differs subtly from a version published...

2014-05-20 08:33:33

PLANTATION, Fla., May 20, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) (the "Company") announced today that it has signed an agreement with Stanford University to study and, along with Dr. Paul Wender, investigate certain analogs of bryostatin, referred to as "bryologs," as potential clinical candidates for the treatment of various neurological disorders. This collaboration is framed by a license agreement forged between Stanford University and Neurotrope, which provides the...

2014-05-19 16:24:18

Appoints Nicholas A. Saccomano, Ph.D. as Chief Scientific Officer and Robert E. Winkler, M.D. as Vice President of Clinical Development BOULDER, Colo., May 19, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, today announced the appointments of Nicholas A. Saccomano, Ph.D., as Chief Scientific Officer and Robert E....

2014-05-19 08:22:41

-- Global Pharmaceutical Consortium Being Created to Expand Predictive Toxicology Resource FREMONT, Calif., May 19, 2014 /PRNewswire/ -- Newly published research demonstrates the ability of BioMAP® Systems, a unique set of primary human cell and co-culture assays that model human disease and pathway biology, to identify important safety aspects of drugs and chemicals more efficiently and accurately than can be achieved by animal testing. Data from BioMAP Systems analysis of 776...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related